Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2024-06-27 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
申万宏源证券承销保荐有限责任公司关于成都欧康医药股份有限公司部分募投项目延期的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal verification opinion from the underwriting and sponsorship institution (申万宏源证券承销保荐有限责任公司) regarding the delay in certain fundraising investment projects of 成都欧康医药股份有限公司. It references regulatory rules related to fundraising and securities issuance, details the fundraising amounts, project progress, reasons for delay, and the approval process by the board and supervisory committee. The document is relatively short (3174 characters) and serves as a verification or supervisory opinion rather than a full financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a transcript or presentation. It is a regulatory compliance-related document verifying the delay in fundraising project progress. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-06-27 Chinese
第四届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the second meeting of the fourth board of directors of Chengdu Oukang Pharmaceutical Co., Ltd. It details the meeting's time, place, attendance, and the approval of a proposal regarding the delay of certain investment projects. The document does not contain financial statements or detailed financial analysis but focuses on board decisions and meeting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management. The document length is short (1275 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2024-06-27 Chinese
关于收到北京证券交易所对公司年报问询函的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Chengdu Oukang Pharmaceutical Co., Ltd. regarding the receipt of an inquiry letter from the Beijing Stock Exchange about the company's 2023 annual report. The content includes detailed questions and requests for explanations about the company's financial performance, asset status, inventory, receivables, payables, export insurance fees, and the establishment of a new overseas subsidiary. It also requests the company's auditors to provide opinions on these matters. The document is a regulatory inquiry related to the annual report but does not contain the annual report itself or its full financial statements. The document length is 3615 characters, which is relatively short and primarily serves as a notice of the inquiry and the company's commitment to respond. Therefore, it is not the annual report (10-K) itself but a regulatory filing announcing the inquiry and the company's forthcoming response. According to the rules, such documents are best classified as Regulatory Filings (RNS).
2024-06-16 Chinese
关于公司通过美国FDA现场检查的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Chengdu Okan Pharmaceutical Co., Ltd. regarding the successful completion of an FDA on-site inspection. It details the inspection dates, scope, and the positive outcome (no FDA-483 observations), emphasizing compliance with FDA standards and the positive impact on the company's market competitiveness. The document is relatively short (843 characters) and serves as a regulatory announcement about the FDA inspection result rather than a detailed report or financial statement. It does not contain financial data, management changes, or voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-13 Chinese
2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an 'Annual Equity Distribution Implementation Announcement' for the year 2023 by Chengdu Oukang Pharmaceutical Co., Ltd. It details the dividend distribution plan approved at the 2024 shareholders' meeting, including dividend amounts, tax deductions, record dates, and payment methods. The document is short (1243 characters) and primarily announces the dividend payment details rather than providing a full financial report or detailed analysis. It also references the shareholders' meeting resolution but does not contain comprehensive financial statements or management discussion. Therefore, this document fits the category of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related details to shareholders.
2024-05-22 Chinese
第四届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the first meeting of the fourth board of directors of Chengdu Oukang Pharmaceutical Co., Ltd. It details the election and appointment of key board members and senior management positions such as chairman, audit committee members, general manager, deputy general manager, board secretary, and financial officer. The document includes voting results and references to related announcements on the Beijing Stock Exchange disclosure platform. There is no financial data or report content; rather, it is an official announcement of board and management changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and it is not a report publication announcement but a substantive announcement of management changes.
2024-05-09 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.